A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure "COMMANDER HF"

Recruiting

Phase 3 Results N/A

Summary of Purpose

The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 November 2017.

10 Sep 2013 12 Jun 2013 14 May 2018 18 May 2018 1 Nov 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:

    JNJ.CT@sylogent.com

  • This study is not yet recruiting patients. Please check back for future recruiting sites, or email

    JNJ.CT@sylogent.com